Harnessing the power of glycan-mediated immune modulation, AviSia Therapeutics develops antigen-specific immunotherapies for the treatment of autoimmune diseases. The company’s initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.